Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 16/20 | 0.81 |
| ▸ | CDK9 | P50750 | 11/20 | 0.81 |
| ▸ | CCNE2 | O96020 | 7/20 | 0.81 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.81 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.81 |
| ▸ | CDK7 | P50613 | 3/20 | 0.81 |
| ▸ | CCNH | P51946 | 3/20 | 0.81 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.81 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.81 |
| ▸ | CDK1 | P06493 | 2/20 | 0.81 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.81 |
| ▸ | CIT | O14578 | 1/20 | 0.81 |
| ▸ | CASK | O14936 | 1/20 | 0.81 |
| ▸ | AURKA | O14965 | 1/20 | 0.81 |
| ▸ | GAK | O14976 | 1/20 | 0.81 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.81 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.81 |
| ▸ | ULK1 | O75385 | 1/20 | 0.81 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.81 |
| ▸ | PAK3 | O75914 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22272122 | 0.93 | CDK2 (0.69) | CDK2CDK9CCNE2CCNE1CCNT1 | |
| SCHEMBL17148368 | 0.91 | CDK2 (0.76) | CDK2CDK9CCNE2CCNE1CCNT1 | |
| Bms-387032 SCHEMBL187401 | 0.90 | CDK2 (1.00) | CDK2CDK9CCNE2CCNE1CCNT1 | |
| SCHEMBL23664185 | 0.89 | CDK2 (0.73) | CDK2CDK9CCNE2CCNE1CCNT1 | |
| Bms-387032 SCHEMBL20583046 | 0.89 | CDK2 (0.98) | CDK2CDK9CCNE2CCNE1CCNT1 | |
| SCHEMBL24528966 | 0.88 | CDK2 (0.83) | CDK2CDK9CCNE2CCNE1CCNT1 | |
| SCHEMBL17141863 | 0.87 | CDK2 (0.70) | CDK2CDK9CCNE2CCNE1CCNT1 | |
| SCHEMBL24758393 | 0.87 | CDK2 (0.83) | CDK2CDK9CCNE2CCNE1CCNT1 | |
| SCHEMBL17141906 | 0.87 | CDK2 (0.88) | CDK2CDK9CCNE2CCNE1CCNT1 | |
| SCHEMBL24528980 | 0.86 | CDK2 (0.79) | CDK2CDK9CCNE2CCNE1CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022129925-A1 | NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| US-20210221814-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. | 2021-07-22 | — | — | US | disclosed |
| US-20210221814-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. | 2021-07-22 | — | — | US | disclosed |
| US-20210107912-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. | 2021-04-15 | — | — | US | disclosed |
| US-20210107912-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. | 2021-04-15 | — | — | US | disclosed |
| EP-3805218-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3805218-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3129371-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2020-07-29 | — | — | EP | disclosed |
| EP-3129371-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2020-07-29 | — | — | EP | disclosed |
| US-20190330218-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2019-10-31 | — | — | US | disclosed |
| US-20190330218-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2019-10-31 | — | — | US | disclosed |
| US-10336760-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-10336760-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20170174692-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-06-22 | — | — | US | disclosed |
| US-20170174692-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-06-22 | — | — | US | disclosed |
| US-20170174692-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-06-22 | — | — | US | disclosed |
| WO-2015154022-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336760-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | CDK2 8/4885CDK9 3/4885CCNE2 62/4885 |
| US-20170174692-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK2 8/4885CDK9 3/4885CCNE2 62/4885 |
| US-20210107912-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK2 8/4885CDK9 3/4885CCNE2 62/4885 |
| US-20210221814-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK2 8/4885CDK9 3/4885CCNE2 62/4885 |
| US-20190330218-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK2 8/4885CDK9 3/4885CCNE2 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.